(R,S)-AM1241

C₂₂H₂₂IN₃O₃

503.33

MFCD11045986

24891092

NA.77

(R,S)-AM1241 has been used as a cannabinoid CB2 agonist:

• to study its inhibitory effect on bone cancer-induced pain and bone loss
• to study the effect of its interaction with 17βestradiol on proliferation activity in primary human osteoblasts
• to evaluate the sites of CB2 mediated antinociception in vivo.

AM1241 acts as an antinociceptive agent in several animal pain models. It has a potential to delay disease progression in amyotrophic lateral sclerosis (ALS) mouse model. Intrathecal, intravenous or intraperitoneal administration of AM1241 reduces hyperalgesia and allodynia in neuropathic rats.
Selective CB₂ cannabinoid receptor agonist

100

≥98% (HPLC)

solid

regulated under CDSA - not available from sigma-aldrich Canada

yellow

DMSO: ~18 mg/mL at 60 ℃

CN1CCCCC1Cn2cc(C(=O)c3cc(ccc3I)[N+]([O-])=O)c4ccccc24

1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3

ZUHIXXCLLBMBDW-UHFFFAOYSA-N

5, 25 mg in glass bottle

GHS07,GHS08

Danger

H315 - H319 - H334 - H335

P302 + P352 - P305 + P351 + P338

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

Respiratory system

11 - Combustible Solids

WGK 3

dust mask type N95 (US), Eyeshields, Faceshields, Gloves